Initial Data on Clinical Use of Generic Romiplostim for Second-Line and Subsequent Therapy of Immune Thrombocytopenia in India

Introduction: Over 50% of adults with immune thrombocytopenia (ITP) require second-line therapy after steroids, but these options are plagued by low rates of response, which are often delayed by 2–3 months. Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that has shown significant efficacy...

Full description

Saved in:
Bibliographic Details
Main Authors: Suvir Singh, Komalpreet Kaur
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Indian Journal of Medical Specialities
Subjects:
Online Access:https://journals.lww.com/10.4103/injms.injms_105_20
Tags: Add Tag
No Tags, Be the first to tag this record!